GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Cascadian Therapeutics Inc (NAS:CASC) » Definitions » Shiller PE Ratio

Cascadian Therapeutics (Cascadian Therapeutics) Shiller PE Ratio : (As of May. 05, 2024)


View and export this data going back to 1991. Start your Free Trial

What is Cascadian Therapeutics Shiller PE Ratio?

Shiller PE for Stocks: The True Measure of Stock Valuation


Cascadian Therapeutics Shiller PE Ratio Historical Data

The historical data trend for Cascadian Therapeutics's Shiller PE Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Cascadian Therapeutics Shiller PE Ratio Chart

Cascadian Therapeutics Annual Data
Trend Dec08 Dec09 Dec10 Dec11 Dec12 Dec13 Dec14 Dec15 Dec16 Dec17
Shiller PE Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Cascadian Therapeutics Quarterly Data
Mar13 Jun13 Sep13 Dec13 Mar14 Jun14 Sep14 Dec14 Mar15 Jun15 Sep15 Dec15 Mar16 Jun16 Sep16 Dec16 Mar17 Jun17 Sep17 Dec17
Shiller PE Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Cascadian Therapeutics's Shiller PE Ratio

For the Biotechnology subindustry, Cascadian Therapeutics's Shiller PE Ratio, along with its competitors' market caps and Shiller PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Cascadian Therapeutics's Shiller PE Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Cascadian Therapeutics's Shiller PE Ratio distribution charts can be found below:

* The bar in red indicates where Cascadian Therapeutics's Shiller PE Ratio falls into.



Cascadian Therapeutics Shiller PE Ratio Calculation

For Shiller PE Ratio, the earnings of the past 10 years are inflation-adjusted and averaged. The result is used for P/E calculation. Since it looks at the average over the last 10 years, the Shiller PE Ratio is also called PE10.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The same calculation is applied here to individual companies.

Cascadian Therapeutics's E10 for the quarter that ended in Dec. 2017 is calculated as:

For example, Cascadian Therapeutics's adjusted earnings per share data for the three months ended in Dec. 2017 was:

Adj_EPS=Earnings per Share (Diluted)/CPI of Dec. 2017 (Change)*Current CPI (Dec. 2017)
=-0.34/104.0111*104.0111
=-0.340

Current CPI (Dec. 2017) = 104.0111.

Cascadian Therapeutics Quarterly Data

Earnings per Share (Diluted) CPI Adj_EPS
200803 -1.555 90.090 -1.795
200806 -1.500 92.320 -1.690
200809 -1.080 92.307 -1.217
200812 6.480 88.697 7.599
200903 -0.780 89.744 -0.904
200906 -1.800 91.003 -2.057
200909 -1.440 91.120 -1.644
200912 -0.480 91.111 -0.548
201003 -0.180 91.821 -0.204
201006 -1.020 91.962 -1.154
201009 -1.020 92.162 -1.151
201012 -2.100 92.474 -2.362
201103 -1.440 94.283 -1.589
201106 -5.460 95.235 -5.963
201109 -0.900 95.727 -0.978
201112 -1.620 95.213 -1.770
201203 1.260 96.783 1.354
201206 -0.900 96.819 -0.967
201209 -0.900 97.633 -0.959
201212 -0.720 96.871 -0.773
201303 -0.840 98.209 -0.890
201306 -1.680 98.518 -1.774
201309 -0.720 98.790 -0.758
201312 -0.480 98.326 -0.508
201403 -0.840 99.695 -0.876
201406 -0.540 100.560 -0.559
201409 -0.540 100.428 -0.559
201412 -2.000 99.070 -2.100
201503 -0.480 99.621 -0.501
201506 -0.660 100.684 -0.682
201509 -0.300 100.392 -0.311
201512 -0.580 99.792 -0.605
201603 -0.810 100.470 -0.839
201606 -1.570 101.688 -1.606
201609 -0.520 101.861 -0.531
201612 -0.390 101.863 -0.398
201703 -0.300 102.862 -0.303
201706 -0.300 103.349 -0.302
201709 -0.280 104.136 -0.280
201712 -0.340 104.011 -0.340

Add all the adjusted EPS together and divide 10 will get our E10.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Cascadian Therapeutics  (NAS:CASC) Shiller PE Ratio Explanation

Compared with the regular PE Ratio, which works poorly for cyclical businesses, the Shiller PE Ratio smoothed out the fluctuations of profit margins during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Shiller PE Ratio should give similar results to regular PE Ratio.

Compared with the PS Ratio, the Shiller PE Ratio makes the comparison between different industries more meaningful.


Be Aware

Shiller PE Ratio assumes that over the long term, businesses and profitability revert to their means. If a company's business model does not work in the future compared with the past, Shiller PE Ratio and PS Ratio will give false valuations.


Cascadian Therapeutics Shiller PE Ratio Related Terms

Thank you for viewing the detailed overview of Cascadian Therapeutics's Shiller PE Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Cascadian Therapeutics (Cascadian Therapeutics) Business Description

Traded in Other Exchanges
N/A
Address
Cascadian Therapeutics Inc is a clinical-stage biopharmaceutical company focusing in developing innovative therapeutic product candidates for the treatment of cancer. Its objective is to discover, develop and commercialize novel compounds that have the potential to improve the lives and outcomes of cancer patients. The company's clinical-stage product candidate includes ONT-380, an orally active and selective small molecule HER2 inhibitor. In addition, it is also engaged in developing preclinical product candidates in oncology using its Checkpoint kinase 1 kinase inhibitor and protocell technology. All the business activity of the firm is functioned through the region of United States.
Executives
Ted W Love director C/O GLOBAL BLOOD THERAPEUTICS, INC., 400 EAST JAMIE COURT, SUITE 101, SOUTH SAN FRANCISCO CA 94080
Gwen A. Fyfe director C/O ARRAY BIOPHARMA INC., 3200 WALNUT STREET, BOULDER CO 80301
Steven P James director C/O OCERA THERAPUETICS, 525 UNIVERSITY AVENUE, SUITE 610, PALO ALTO CA 94301
Julia Marie Eastland officer: CFO & CBO C/O CASCADIAN THERAPEUTICS, INC., 3101 WESTERN AVE., SUITE 600, SEATTLE WA 98121
Christopher S Henney director 10505 ROSELLE STREET, SAN DIEGO CA 92121
Robert Azelby director 307 WESTLAKE AVE. NORTH, STE 300, SEATTLE WA 98109
Daniel K Spiegelman director MYRIAD GENETICS, 320 WAKARA WAY, SALT LAKE CITY UT 84003
Scott Dunseth Myers director, officer: President and CEO C/O CASCADIAN THERAPEUTICS, INC., 3101 WESTERN AVE., SUITE 600, SEATTLE WA 98121
Growth Equity Opportunities Iv, Llc 10 percent owner 1954 GREENSPRING DRIVE, SUITE 600, TIMONIUM MD 21093
Nea 15 Gp, Llc 10 percent owner 1954 GREENSPRING DRIVE, SUITE 600, TIMONIUM MD 21093
Nea Partners 15, L.p. 10 percent owner 1954 GREENSPRING DRIVE, SUITE 600, TIMONIUM MD 21093
New Enterprise Associates 15, L.p. 10 percent owner 1954 GREENSPRING DRIVE, SUITE 600, TIMONIUM MD 21093
Jon Sakoda 10 percent owner 2855 SAND HILL ROAD, MENLO PARK CA 94025
Florence Anthony A. Jr. 10 percent owner 5425 WISCONSIN AVENUE, SUITE 800, CHEVY CHASE MD 20815
Peter W. Sonsini 10 percent owner 2855 SAND HILL ROAD, MENLO PARK CA 94025

Cascadian Therapeutics (Cascadian Therapeutics) Headlines

From GuruFocus

Seth Klarman Buys 25 Million Shares of Cascadian Therapeutics

By Kyle Ferguson Kyle Ferguson 07-11-2016